← All trials
NCT05191186
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2020
- Primary completion
- Aug 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- Jan 13, 2022
- Last posted
- Jan 13, 2022
- Enrollment
- 450
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Aarhus UniversityLead sponsor
- Aarhus UniversityCollaborator
- Aarhus UniversityOverall official - principal investigator
- Aarhus UniversityReponsible party - principal investigator
- Linkoping UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.